1.    PRODUCT OVERVIEW

1.1.  MARKET DEFINITION

1.2.  SCOPE OF THE MARKET

1.2.1.    MARKETS COVERED

1.2.2.    YEARS CONSIDERED FOR STUDY

1.2.3.    KEY MARKET SEGMENTATIONS

2.    RESEARCH METHODOLOGY

2.1.  OBJECTIVE OF THE STUDY

2.2.  BASELINE METHODOLOGY

2.3.  KEY INDUSTRY PARTNERS

2.4.  MAJOR ASSOCIATION AND SECONDARY SOURCES

2.5.  FORECASTING METHODOLOGY

2.6.  DATA TRIANGULATION & VALIDATION

2.7.  ASSUMPTIONS AND LIMITATIONS

3.    EXECUTIVE SUMMARY

3.1.  OVERVIEW OF THE MARKET

3.2.  OVERVIEW OF KEY MARKET SEGMENTATIONS

3.3.  OVERVIEW OF KEY MARKET PLAYERS

3.4.  OVERVIEW OF KEY REGIONS/COUNTRIES

3.5.  OVERVIEW OF MARKET DRIVERS, CHALLENGES, TRENDS

4.    VOICE OF CUSTOMER

5.     JAPAN RHEUMATOLOGY DRUGS MARKET OUTLOOK

5.1.  MARKET SIZE & FORECAST

5.1.1.    BY VALUE

5.2.  MARKET SHARE & FORECAST

5.2.1.    BY DRUG CLASS (DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), CORTICOSTEROIDS, URIC ACIDS, OTHERS)

5.2.2.    BY ROUTE OF ADMINISTRATION (ORAL, PARENTAL)

5.2.3.    BY SALES CHANNEL (PRESCRIPTION-BASED DRUGS, OTC)

5.2.4.    BY REGION

5.2.5.    BY COMPANY 

5.3.  MARKET MAP

6.    HOKKAIDO RHEUMATOID DRUGS MARKET OUTLOOK

6.1.  MARKET SIZE & FORECAST

6.1.1.    BY VALUE

6.2.  MARKET SHARE & FORECAST

6.2.1.    BY MOLECULE TYPE

6.2.2.    BY DRUG CLASS

6.2.3.    BY DISTRIBUTION CHANNEL

7.    TOHOKU RHEUMATOID DRUGS MARKET OUTLOOK

7.1.  MARKET SIZE & FORECAST

7.1.1.    BY VALUE

7.2.  MARKET SHARE & FORECAST

7.2.1.    BY MOLECULE TYPE

7.2.2.    BY DRUG CLASS

7.2.3.    BY DISTRIBUTION CHANNEL

8.    KANTO RHEUMATOID DRUGS MARKET OUTLOOK

8.1.  MARKET SIZE & FORECAST

8.1.1.    BY VALUE

8.2.  MARKET SHARE & FORECAST

8.2.1.    BY MOLECULE TYPE

8.2.2.    BY DRUG CLASS

8.2.3.    BY DISTRIBUTION CHANNEL

9.    CHUBU RHEUMATOID DRUGS MARKET OUTLOOK

9.1.  MARKET SIZE & FORECAST

9.1.1.    BY VALUE

9.2.  MARKET SHARE & FORECAST

9.2.1.    BY MOLECULE TYPE

9.2.2.    BY DRUG CLASS

9.2.3.    BY DISTRIBUTION CHANNEL

10. KANSAI RHEUMATOID DRUGS MARKET OUTLOOK

10.1.   MARKET SIZE & FORECAST        

10.1.1. BY VALUE

10.2.   MARKET SHARE & FORECAST

10.2.1. BY MOLECULE TYPE

10.2.2. BY DRUG CLASS

10.2.3. BY DISTRIBUTION CHANNEL

11. CHUGOKU RHEUMATOID DRUGS MARKET OUTLOOK

11.1.   MARKET SIZE & FORECAST        

11.1.1. BY VALUE

11.2.   MARKET SHARE & FORECAST

11.2.1. BY MOLECULE TYPE

11.2.2. BY DRUG CLASS

11.2.3. BY DISTRIBUTION CHANNEL

12. SHIKOKU RHEUMATOID DRUGS MARKET OUTLOOK

12.1.   MARKET SIZE & FORECAST        

12.1.1. BY VALUE

12.2.   MARKET SHARE & FORECAST

12.2.1. BY MOLECULE TYPE

12.2.2. BY DRUG CLASS

12.2.3. BY DISTRIBUTION CHANNEL

13. KYUSHU RHEUMATOID DRUGS MARKET OUTLOOK

13.1.   MARKET SIZE & FORECAST        

13.1.1. BY VALUE

13.2.   MARKET SHARE & FORECAST

13.2.1. BY MOLECULE TYPE

13.2.2. BY DRUG CLASS

13.2.3. BY DISTRIBUTION CHANNEL

14. MARKET DYNAMICS

14.1.   DRIVERS

14.2.   CHALLENGES

15. MARKET TRENDS & DEVELOPMENTS

15.1.   RECENT DEVELOPMENTS

15.2.   PRODUCT LAUNCHES

15.3.   MERGERS & ACQUISITIONS

16.  JAPAN RHEUMATOLOGY DRUGS MARKET: SWOT ANALYSIS

17. COMPETITIVE LANDSCAPE

17.1.   TAISHO PHARMACEUTICALS

17.1.1.       BUSINESS OVERVIEW

17.1.2.       PRODUCT & SERVICE OFFERINGS

17.1.3.       RECENT DEVELOPMENTS

17.1.4.       FINANCIALS (IF LISTED)

17.1.5.       KEY PERSONNEL

17.1.6.       SWOT ANALYSIS

17.2.   R-PHARM

17.3.   GLAXOSMITHKLINE

17.4.   ACLARIS THERAPEUTICS

17.5.   PFIZER

17.6.   ABIVAX

17.7.   BRISTOL-MYERS SQUIBB

17.8.   MESOBLAST

17.9.  PFIZER AKROS PHARMA/JAPAN TOBACCO

17.10. ABBVIE

17.11. HORIZON THERAPEUTICS

17.12. ELI LILLY AND COMPANY

17.13. TAIHO PHARMACEUTICAL

17.14. GILEAD SCIENCES

17.15. KINIKSA PHARMACEUTICAL

18. STRATEGIC RECOMMENDATIONS

19. ABOUT US & DISCLAIMER